173 related articles for article (PubMed ID: 20370452)
41. Lack of correlation between nasal cultures positive for Staphylococcus aureus and the development of S. aureus exit-site infections: results unaffected by routine mupirocin treatment of nasal S. aureus carriage.
Hanslik TM; Newman L; Tessman M; Morrissey AB; Friedlander MA
Adv Perit Dial; 1994; 10():158-62. PubMed ID: 7999817
[TBL] [Abstract][Full Text] [Related]
42. Effect of sodium fusidate and ofloxacin on Staphylococcus aureus colonization and infection in patients on continuous ambulatory peritoneal dialysis.
Sesso R; Parisio K; Dalboni A; Rabelo T; Barbosa D; Cendoroglo M; Pignatari A; Draibe S; Ajzen H
Clin Nephrol; 1994 Jun; 41(6):370-6. PubMed ID: 8076441
[TBL] [Abstract][Full Text] [Related]
43. Clinical Value of Screening Peritoneal Dialysis Patients for Bacterial Colonization or Contamination.
Parthasarathy R; Kashem T; NicFhogartaigh C; Melzer M; Fan SL
Perit Dial Int; 2019; 39(2):126-133. PubMed ID: 30739095
[TBL] [Abstract][Full Text] [Related]
44. An integrated critique of the efficacy of topical mupirocin in preventing catheter-related Staphylococcus aureus infections in peritoneal dialysis clients.
Pratt O
CANNT J; 2002; 12(1):20-8. PubMed ID: 11979650
[TBL] [Abstract][Full Text] [Related]
45. Prevention of peritonitis in peritoneal dialysis.
Segal JH; Messana JM
Semin Dial; 2013; 26(4):494-502. PubMed ID: 23859192
[TBL] [Abstract][Full Text] [Related]
46. Exit-site/tunnel infection and catheter outcome in peritoneal dialysis patients.
Wadhwa NK; Cabralda T; Suh H; Kvilekval K; Mason R
Adv Perit Dial; 1992; 8():325-7. PubMed ID: 1361816
[TBL] [Abstract][Full Text] [Related]
47. Prevention of staphylococcal peritonitis in CAPD patients combining ablution and mupirocin.
Al-Hwiesh AK; Abdul Rahman IS
Saudi J Kidney Dis Transpl; 2008 Sep; 19(5):737-45. PubMed ID: 18711288
[TBL] [Abstract][Full Text] [Related]
48. Effect of preventing Staphylococcus aureus carriage on rates of peritoneal catheter-related staphylococcal infections. Literature synthesis.
Ritzau J; Hoffman RM; Tzamaloukas AH
Perit Dial Int; 2001; 21(5):471-9. PubMed ID: 11757831
[TBL] [Abstract][Full Text] [Related]
49. Epidemiology, management, and prevention of exit site infections in peritoneal dialysis patients.
Sachar M; Shah A
Ther Apher Dial; 2022 Apr; 26(2):275-287. PubMed ID: 34435734
[TBL] [Abstract][Full Text] [Related]
50. Recurrent and relapsing peritonitis: causative organisms and response to treatment.
Szeto CC; Kwan BC; Chow KM; Law MC; Pang WF; Chung KY; Leung CB; Li PK
Am J Kidney Dis; 2009 Oct; 54(4):702-10. PubMed ID: 19577352
[TBL] [Abstract][Full Text] [Related]
51. Long-Term Exit-Site Gentamicin Prophylaxis and Gentamicin Resistance in a Peritoneal Dialysis Program.
Chen SS; Sheth H; Piraino B; Bender F
Perit Dial Int; 2016; 36(4):387-9. PubMed ID: 26634567
[TBL] [Abstract][Full Text] [Related]
52. Mupirocin for preventing exit-site infection and peritonitis in patients undergoing peritoneal dialysis. Was it effective?
Piraino B
Nephrol Dial Transplant; 2010 Feb; 25(2):349-52. PubMed ID: 19934078
[No Abstract] [Full Text] [Related]
53. Subcutaneous cuff removal in persistent exit-site/tunnel infections in peritoneal dialysis.
Suh H; Wadhwa NK; Cabralda T
Adv Perit Dial; 1995; 11():157-9. PubMed ID: 8534693
[TBL] [Abstract][Full Text] [Related]
54. A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin.
Bernardini J; Piraino B; Holley J; Johnston JR; Lutes R
Am J Kidney Dis; 1996 May; 27(5):695-700. PubMed ID: 8629630
[TBL] [Abstract][Full Text] [Related]
55. Application of mupirocin cream at the catheter exit site reduces exit-site infections and peritonitis in peritoneal dialysis patients.
Casey M; Taylor J; Clinard P; Graham A; Mauck V; Spainhour L; Brown P; Burkart J
Perit Dial Int; 2000; 20(5):566-8. PubMed ID: 11117248
[No Abstract] [Full Text] [Related]
56. Staphylococcus aureus infections during peritoneal dialysis.
Coles GA
J Chemother; 1995 Jul; 7 Suppl 3():67-70. PubMed ID: 8609540
[TBL] [Abstract][Full Text] [Related]
57. Topical mupirocin/sodium hypochlorite reduces peritonitis and exit-site infection rates in children.
Chua AN; Goldstein SL; Bell D; Brewer ED
Clin J Am Soc Nephrol; 2009 Dec; 4(12):1939-43. PubMed ID: 19820132
[TBL] [Abstract][Full Text] [Related]
58. Persistent exit-site/tunnel infection and subcutaneous cuff removal in PD patients.
Suh H; Wadhwa NK; Cabralda T; Bonanno J; Wasiluk A; Sorrento J
Adv Perit Dial; 1997; 13():233-6. PubMed ID: 9360689
[TBL] [Abstract][Full Text] [Related]
59. The risk of peritonitis after an exit site infection: a time-matched, case-control study.
Lloyd A; Tangri N; Shafer LA; Rigatto C; Perl J; Komenda P; Sood MM
Nephrol Dial Transplant; 2013 Jul; 28(7):1915-21. PubMed ID: 23382265
[TBL] [Abstract][Full Text] [Related]
60. Microbial spectrum and outcome of peritoneal dialysis related peritonitis in Qatar.
Shigidi MM; Fituri OM; Chandy SK; Asim M; Al Malki HA; Rashed AH
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):168-73. PubMed ID: 20061719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
